Evotec (NASDAQ:EVO) Shares Cross Above 50 Day Moving Average – Here’s What Happened

Evotec AG (NASDAQ:EVO) shares crossed above its fifty day moving average during trading on Thursday. The stock has a fifty day moving average of $1.62 and traded as high as $1.82. Evotec shares last traded at $1.7750, with a volume of 273,618 shares.

Key Headlines Impacting Evotec

Here are the key news stories impacting Evotec this week:

• Positive Sentiment: Evotec’s Q3 adjusted EBITDA loss narrowed to €1.6 million. Revenue was €164.9 million, and the company also beat analyst expectations for quarterly revenue and EPS. Evotec Q3 and nine-month results
• Positive Sentiment: The company reaffirmed its FY2026 guidance. It also reported 24% growth in D&PD base-business net sales, pointing to commercial momentum. Evotec Q3 EBITDA and guidance
• Neutral Sentiment: Evotec highlighted a new Vertex manufacturing mandate, which could support future business, though the articles provided no financial details about the contract. Vertex manufacturing mandate and RBC target
• Negative Sentiment: Evotec cut and slightly postponed its 2030 revenue ambitions, tempering the longer-term growth outlook despite the quarterly improvement. Evotec cuts 2030 revenue target
• Negative Sentiment: RBC reduced its price target to €5, adding to investor concerns about the outlook. A report also noted a reduced JPMorgan stake, though the supplied details do not specify the size or rationale. Analyst target and JPMorgan stake report

Analyst Upgrades and Downgrades

EVO has been the topic of several recent research reports. Berenberg Bank lowered Evotec from a “buy” rating to a “hold” rating in a report on Thursday, July 16th. Weiss Ratings downgraded Evotec from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, August 25th. TD Cowen downgraded Evotec from a “buy” rating to a “hold” rating and set a $2.00 price target for the company. in a research note on Wednesday, July 15th. Finally, HC Wainwright reissued a “buy” rating and set a $4.00 price objective on shares of Evotec in a report on Wednesday, October 14th. One research analyst has rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Evotec currently has an average rating of “Hold” and an average target price of $3.00.

Evotec Stock Up 13.1%

The firm has a fifty day simple moving average of $1.62 and a 200 day simple moving average of $2.49. The company has a quick ratio of 2.21, a current ratio of 2.33 and a debt-to-equity ratio of 0.62.

Hedge Funds Weigh In On Evotec

Institutional investors have recently added to or reduced their stakes in the company. Optiver Holding B.V. boosted its position in Evotec by 598.4% in the first quarter. Optiver Holding B.V. now owns 283,576 shares of the company’s stock valued at $709,000 after buying an additional 242,973 shares in the last quarter. WCM Investment Management LLC increased its holdings in shares of Evotec by 12.1% during the first quarter. WCM Investment Management LLC now owns 627,260 shares of the company’s stock worth $1,480,000 after buying an additional 67,917 shares in the last quarter. Finally, Apollon Wealth Management LLC acquired a new stake in shares of Evotec during the first quarter worth approximately $28,000. 5.81% of the stock is owned by institutional investors.

About Evotec

Evotec SE is a Germany-based biotechnology company that provides drug discovery and development services to pharmaceutical, biotechnology and academic research organizations. The company combines scientific expertise, proprietary technologies and integrated research platforms to identify and advance potential medicines across multiple therapeutic areas, including neuroscience, oncology, metabolic disease, infectious disease and inflammation.

Evotec’s activities span early-stage target identification, compound screening, medicinal chemistry, pharmacology, preclinical research and selected clinical development services.